Palmitoyl Pentapeptide-4

A lipopeptide consisting of a palmitoyl group attached to the pentapeptide KTTKS, a fragment of type I procollagen. Branded as Matrixyl, it is one of the most commercially successful cosmetic peptides, clinically shown to stimulate collagen synthesis and reduce wrinkle depth. The palmitoyl group enhances skin penetration by increasing lipophilicity.

• KTTKS fragment mimics collagen breakdown products to trigger wound-healing response
• Activates TGF-beta signaling in fibroblasts to upregulate collagen gene expression
• Stimulates glycosaminoglycan synthesis for improved skin hydration
• Palmitoyl anchor facilitates stratum corneum penetration and dermal delivery

• Known allergy to any component of the formulation
• Open wounds or severely compromised skin barrier (apply only to intact skin)

Store topical formulations at room temperature (15–25°C (59–77°F)) away from sunlight. Concentrated solutions: keep at 2–8°C (36–46°F). Stable for 12-24 months in properly formulated products.

Developed by Sederma (now part of Croda), Matrixyl was introduced in 2000 and became one of the first clinically validated cosmetic peptides. A landmark double-blind study demonstrated that 8 weeks of topical application reduced wrinkle volume by 36% and wrinkle depth by 27% compared to placebo. Subsequent studies confirmed collagen synthesis stimulation in ex vivo human skin models. It remains one of the best-studied and most widely used peptides in anti-aging skincare.